Short Wave

A Surprising Cause Of Endometriosis Could Lead To Cure

September 26, 2025

Key Takeaways Copied to clipboard!

  • Katie Burns's research indicated that the immune system, specifically innate immune cells like neutrophils and macrophages, is a critical initial factor in the establishment of endometriosis lesions, challenging the long-held primary focus on estrogen. 
  • The immune system's role in endometriosis involves deficiencies in natural killer cells and inflammatory, non-clearing neutrophils and macrophages, suggesting new avenues for targeted, non-hormonal treatments. 
  • Researchers are developing non-invasive diagnostic tests for endometriosis by analyzing menstrual fluid, which could replace the current necessity of surgery for a definitive diagnosis. 

Segments

Katie Burns’s Pain History
Copied to clipboard!
(00:00:22)
  • Key Takeaway: Katie Burns experienced debilitating pain starting around age 10, leading to an emergency room visit for suspected appendicitis before receiving an endometriosis diagnosis at age 20.
  • Summary: Katie Burns recalls being frequently sick as a child, followed by severe abdominal pain starting around age 10. Menstruation significantly worsened her symptoms, though adults dismissed the pain as normal growing pains. She finally received an endometriosis diagnosis at age 20, which was validating but did not immediately offer relief.
Immune System Discovery
Copied to clipboard!
(00:02:25)
  • Key Takeaway: Experiments showed that endometriosis lesions could develop in mice even when estrogen receptors were absent and estrogen influence was removed, pointing away from hormones as the sole initial cause.
  • Summary: Previous theories centered on hormones driving endometriosis, but Katie Burns’s work challenged this by observing lesion development in mice engineered to lack estrogen receptors and be estrogen-deprived. This suggested another factor was crucial for the initial establishment of the tissue. Subsequent observation revealed that innate immune cells, specifically neutrophils and macrophages, flood the pelvic cavity within the first 24 to 48 hours after tissue implantation.
Immune System’s Role Detailed
Copied to clipboard!
(00:09:08)
  • Key Takeaway: Immune cells in endometriosis patients are dysfunctional: natural killer cells fail to target misplaced tissue, while neutrophils and macrophages become inflammatory or nurturing instead of clearing the ectopic cells.
  • Summary: Scientists have found that natural killer cells are fewer in number and less effective at destroying misplaced endometrial tissue. Neutrophils linger and become inflammatory rather than performing their necessary cleanup function. Macrophages, instead of vacuuming up errant cells, actively nurture the tissue as it embeds in inappropriate locations.
Future Treatment Avenues
Copied to clipboard!
(00:10:19)
  • Key Takeaway: Targeting the immune system offers promising new treatment pathways, such as using antibodies against inflammatory cytokines or drugs like nibrozetone to improve macrophage cleanup function.
  • Summary: Because the immune system is implicated, new drug targets are possible that could be more effective than current estrogen therapies. One approach involves manufacturing antibodies to attack specific inflammatory products, known as cytokines, to calm the inflammation driving pain. Another approach involves drugs, like nibrozetone currently in human trials, designed to enhance the ability of macrophages to clean up misplaced cells.
Diagnostic Progress and Funding Woes
Copied to clipboard!
(00:11:46)
  • Key Takeaway: Researchers are close to developing a non-invasive diagnostic test for endometriosis using menstrual fluid, but the field suffers from critically low funding from major bodies like the NIH.
  • Summary: Pioneering work at the Feinstein Institutes is leading toward a diagnostic test based on analyzing menstrual fluid, which is vital because surgery is currently the only way to achieve an ironclad diagnosis. Despite significant research progress, the field faces funding uncertainty, with the NIH allocating only about 0.03% of its budget to this disease in 2024.